TY - JOUR T1 - Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity that may underly population disparities in this disease JF - bioRxiv DO - 10.1101/2020.04.12.037622 SP - 2020.04.12.037622 AU - Yong-Fei Wang AU - Yan Zhang AU - Zhiming Lin AU - Huoru Zhang AU - Ting-You Wang AU - Yujie Cao AU - David L. Morris AU - Yujun Sheng AU - Xianyong Yin AU - Shi-Long Zhong AU - Xiaoqiong Gu AU - Yao Lei AU - Jing He AU - Qi Wu AU - Jiangshan Jane Shen AU - Jing Yang AU - Tai-Hing Lam AU - Jia-Huang Lin AU - Zhi-Ming Mai AU - Mengbiao Guo AU - Yuanjia Tang AU - Yanhui Chen AU - Qin Song AU - Bo Ban AU - Chi Chiu Mok AU - Yong Cui AU - Liangjing Lu AU - Nan Shen AU - Pak C. Sham AU - Chak Sing Lau AU - David K. Smith AU - Timothy J. Vyse AU - Xuejun Zhang AU - Yu Lung Lau AU - Wanling Yang Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/04/12/2020.04.12.037622.abstract N2 - Systemic lupus erythematosus (SLE), a worldwide autoimmune disease with high heritability, shows differences in prevalence, severity and age of onset among different ancestral groups. Previous genetic studies have focused more on European populations, which appear to be the least affected. Consequently, the genetic variations that underly the commonalities, differences and treatment options in SLE among ancestral groups have not been well elucidated. To address this, we undertook a genome-wide association study, increasing the sample size of Chinese populations to the level of existing European studies. Thirty-eight novel SLE-associated loci and incomplete sharing of genetic architecture were identified. Nine disease loci showed clear ancestral group heterogeneity and implicated antibody production as a potential mechanism for differences in disease manifestation. Polygenic risk scores performed significantly better when trained on matched ancestral data sets. These analyses help to reveal the genetic bases for disparities in SLE among ancestral groups.Competing Interest StatementThe authors have declared no competing interest. ER -